🚀 VC round data is live in beta, check it out!
Emcure Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Emcure Pharmaceuticals and similar public comparables like Oruka Therapeutics, Yili Chuannig Biotech, Dyne Therapeutics, Kiniksa Pharmaceuticals and more.
Emcure Pharmaceuticals Overview
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women’s Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
Founded
1981
HQ
Employees
6.7K
Website
Sectors
Financials (LTM)
EV
$4B
Emcure Pharmaceuticals Financials
Emcure Pharmaceuticals reported last 12-month revenue of $992M and EBITDA of $194M.
In the same LTM period, Emcure Pharmaceuticals generated $599M in gross profit, $194M in EBITDA, and $106M in net income.
Revenue (LTM)
Emcure Pharmaceuticals P&L
In the most recent fiscal year, Emcure Pharmaceuticals reported revenue of $918M and EBITDA of $171M.
Emcure Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $992M | XXX | $918M | XXX | XXX | XXX |
| Gross Profit | $599M | XXX | $482M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $194M | XXX | $171M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $106M | XXX | $81M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $66M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Emcure Pharmaceuticals Stock Performance
Emcure Pharmaceuticals has current market cap of $3B, and enterprise value of $4B.
Market Cap Evolution
Emcure Pharmaceuticals' stock price is $17.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $3B | 2.3% | XXX | XXX | XXX | $0.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEmcure Pharmaceuticals Valuation Multiples
Emcure Pharmaceuticals trades at 3.5x EV/Revenue multiple, and 18.2x EV/EBITDA.
EV / Revenue (LTM)
Emcure Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Emcure Pharmaceuticals has market cap of $3B and EV of $4B.
Equity research analysts estimate Emcure Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Emcure Pharmaceuticals has a P/E ratio of 32.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 18.2x | XXX | 20.6x | XXX | XXX | XXX |
| EV/EBIT | 23.5x | XXX | 27.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | 7.3x | XXX | XXX | XXX |
| P/E | 32.2x | XXX | 42.0x | XXX | XXX | XXX |
| EV/FCF | 66.7x | XXX | 73.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Emcure Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Emcure Pharmaceuticals Margins & Growth Rates
Emcure Pharmaceuticals' revenue in the last 12 month grew by 13%.
Emcure Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Emcure Pharmaceuticals' rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emcure Pharmaceuticals' rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Emcure Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Emcure Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Emcure Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Oruka Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Yili Chuannig Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Dyne Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kiniksa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hubei Jumpcan | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emcure Pharmaceuticals M&A Activity
Emcure Pharmaceuticals acquired XXX companies to date.
Last acquisition by Emcure Pharmaceuticals was on XXXXXXXX, XXXXX. Emcure Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Emcure Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEmcure Pharmaceuticals Investment Activity
Emcure Pharmaceuticals invested in XXX companies to date.
Emcure Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Emcure Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Emcure Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Emcure Pharmaceuticals
| When was Emcure Pharmaceuticals founded? | Emcure Pharmaceuticals was founded in 1981. |
| Where is Emcure Pharmaceuticals headquartered? | Emcure Pharmaceuticals is headquartered in India. |
| How many employees does Emcure Pharmaceuticals have? | As of today, Emcure Pharmaceuticals has over 6K employees. |
| Who is the CEO of Emcure Pharmaceuticals? | Emcure Pharmaceuticals' CEO is Satish Ramanlal Mehta. |
| Is Emcure Pharmaceuticals publicly listed? | Yes, Emcure Pharmaceuticals is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Emcure Pharmaceuticals? | Emcure Pharmaceuticals trades under EMCURE ticker. |
| When did Emcure Pharmaceuticals go public? | Emcure Pharmaceuticals went public in 2024. |
| Who are competitors of Emcure Pharmaceuticals? | Emcure Pharmaceuticals main competitors are Oruka Therapeutics, Yili Chuannig Biotech, Dyne Therapeutics, Kiniksa Pharmaceuticals. |
| What is the current market cap of Emcure Pharmaceuticals? | Emcure Pharmaceuticals' current market cap is $3B. |
| What is the current revenue of Emcure Pharmaceuticals? | Emcure Pharmaceuticals' last 12 months revenue is $992M. |
| What is the current revenue growth of Emcure Pharmaceuticals? | Emcure Pharmaceuticals revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Emcure Pharmaceuticals? | Current revenue multiple of Emcure Pharmaceuticals is 3.5x. |
| Is Emcure Pharmaceuticals profitable? | Yes, Emcure Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Emcure Pharmaceuticals? | Emcure Pharmaceuticals' last 12 months EBITDA is $194M. |
| What is Emcure Pharmaceuticals' EBITDA margin? | Emcure Pharmaceuticals' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Emcure Pharmaceuticals? | Current EBITDA multiple of Emcure Pharmaceuticals is 18.2x. |
| What is the current FCF of Emcure Pharmaceuticals? | Emcure Pharmaceuticals' last 12 months FCF is $53M. |
| What is Emcure Pharmaceuticals' FCF margin? | Emcure Pharmaceuticals' last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Emcure Pharmaceuticals? | Current FCF multiple of Emcure Pharmaceuticals is 66.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.